Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
617 articles by Ben Fidler
-
Contineum, a startup born from a Roche buyout, files for IPO
March 17, 2024 -
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
March 15, 2024 -
Madrigal wins FDA approval of first drug for MASH
March 14, 2024 -
J&J, Novo support Asgard’s push to make ‘in vivo’ cell therapies
March 14, 2024 -
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
March 12, 2024 -
Biotech stock fundings headed for best quarter in 3 years, Jefferies says
March 11, 2024 -
FDA clears use of Novo’s obesity drug to protect heart health
March 8, 2024 -
Biotech IPOs heated up to start 2024. Will the surge last?
March 5, 2024 -
Akero strengthens MASH drug’s case with new study data
March 4, 2024 -
Bayer pays $310M to buy into BridgeBio heart drug
March 4, 2024 -
Gritstone to lay off 40% of workforce after costly study delay
March 1, 2024 -
Obesity drug from Boehringer, Zealand succeeds in MASH trial
Feb. 26, 2024 -
BioMarin preaches patience amid slow sales for hemophilia gene therapy
Feb. 23, 2024 -
ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund
Feb. 22, 2024 -
NEJM paper fills in details on ‘remarkable’ CAR-T result in autoimmune disease
Feb. 21, 2024 -
Iovance, with approval of ‘TIL’ cell therapy, readies for complex launch
Feb. 20, 2024 -
Gilead reviewing drug acquired in $5B buyout after latest setback
Feb. 16, 2024 -
Alnylam changes to heart drug trial spark doubts, sinking shares
Feb. 15, 2024 -
Kalvista pill succeeds in late-stage study for rare swelling disorder
Feb. 13, 2024 -
Kyverna CEO Peter Maag on courting investors in a ‘volatile’ IPO market
Feb. 9, 2024 -
Kyverna IPO adds to biotech momentum with $319M fundraise
Feb. 7, 2024 -
MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte
Feb. 6, 2024 -
Arch, a prolific biotech creator, is raising $3B for startup investing
Feb. 2, 2024 -
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
Jan. 30, 2024 -
CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
Jan. 30, 2024